## Policies for the Commissioning of Healthcare

### Policy for surgical treatment of carpal tunnel syndrome

<table>
<thead>
<tr>
<th>Introduction</th>
</tr>
</thead>
<tbody>
<tr>
<td>This document is part of a suite of policies that the CCG uses to drive its commissioning of healthcare. Each policy in that suite is a separate public document in its own right but will be applied with reference to other policies in that suite.</td>
</tr>
</tbody>
</table>

| This policy is based on the CCGs Statement of Principles for Commissioning of Healthcare (version in force on the date on which this policy is adopted). |

### 1 Policy

1.1 The CCG will commission surgical release of the carpal tunnel in the following circumstances¹:

1.1.1 The documented specialist opinion is that the likely benefit from surgery outweighs the risk of harm for the patient AND EITHER

1.1.2.1 There is permanent reduction in sensation in the median nerve distribution OR

1.1.2.2 There is muscle wasting or weakness of thenar abduction OR

1.1.2.3 The patient has severe progressive carpal tunnel syndrome and the documented specialist opinion is that surgery is needed promptly to prevent irreversible median nerve/muscle damage OR

1.1.2.4 The patient has sleep disturbance or limited ability to undertake activities of daily living due to symptom severity AND

1.1.3 The patient's symptoms have not resolved despite 8 weeks of conservative treatment, including activity modification and either nocturnal wrist splinting or a single steroid injection (unless contraindicated) AND

1.1.4 The diagnosis of carpal tunnel syndrome has been confirmed, either clinically by scored questionnaire or by nerve conduction studies if not possible by examination AND

1.1.5 In the case of patients with mild to moderate carpal tunnel for whom symptom onset occurred during pregnancy, the patient must be at least 12 weeks post-partum.

1.2 The CCG recognises that the type of surgical procedure undertaken (endoscopic or open surgery) will depend both on clinical factors (including the presence of swelling over the carpal tunnel) and the experience of the surgeon.

### 2 Scope and definitions
This policy relates to the surgical release of the carpal tunnel as a treatment for carpal tunnel syndrome.

Carpal tunnel syndrome (CTS) is a relatively common condition caused by compression of the median nerve within the carpal tunnel in the wrist. This can arise for a variety of reasons, including fluid retention, particularly in pregnancy. This gives rise to pain, numbness or tingling in the thumb, index and middle fingers. In severe cases it may cause nerve damage and weakness/wasting of the muscles of the hand, especially the thumb (thenar wasting). Patients often report their symptoms are worse at night and may disturb sleep.

The role of electrophysiology in the diagnosis/treatment of carpal tunnel syndrome is the subject of ongoing debate. BOA/RCS guidance suggests it should be used, where there is diagnostic doubt, to aid the selection of patients for surgery and to monitor the success of surgery. Symptoms do not necessarily progressively worsen and, in up to a third of cases, will resolve without treatment or with simple self-care. Carpal tunnel syndrome in pregnancy often resolves within 12 weeks of delivery, but 50% of women have persisting symptoms at 1 year. Non-surgical treatments, such as steroid injections or wrist splints, are used to treat mild to moderate symptoms. Surgical release (decompression) of the carpal tunnel may be carried out if non-surgical approaches fail to relieve symptoms.

The scope of this policy includes requests for decompressing the carpal tunnel by either open or arthroscopic surgical techniques.

The CCG recognises that a patient may:

- suffer from carpal tunnel syndrome,
- wish to have a service provided for their condition,
- be advised that they are clinically suitable for surgical release of the carpal tunnel, and
- be distressed by their condition, and by the fact that they may not meet the criteria specified in this commissioning policy.

Such features place the patient within the group to whom this policy applies and do not make them exceptions to it.

The CCG considers that the purpose of surgical release of the carpal tunnel is to improve the health of patients by reducing pain, discomfort and disability.

The CCG regards the achievement of this purpose as according with the Principle of Appropriateness. Therefore, this policy does not rely on the principle of appropriateness. Nevertheless, if a patient is considered exceptional in relation to the principles on which the policy does rely, the CCG may consider the principle of appropriateness in the particular circumstances of the patient in question when considering an application to
The CCG considers that there is some evidence for the effectiveness and cost effectiveness of non-surgical management options.

For some patients, a single local corticosteroid injection has been shown to be effective for short term symptomatic relief in mild to moderate cases, but evidence suggests repeat injections may not provide significant added clinical benefit. For some patients, wrist splinting in the neutral position may alleviate the symptoms of carpal tunnel syndrome with few complications. One study in which patients were randomised to splinting or to surgery reported splinting provided symptom relief and avoided surgery for 37% of patients. However, there is limited evidence on its effectiveness in comparison with other methods of conservative management or for the effectiveness of different designs or regimes of splint wearing.

The CCG considers that there is sufficient evidence with which to draw firm conclusions regarding the effectiveness of surgical release of the carpal tunnel.

The CCG considers that surgical release of the carpal tunnel is more effective at relieving symptoms than splinting. However, splinting can provide relief of symptoms, particularly overnight, for patients with mild to moderate carpal tunnel syndrome and is a relatively simple, low cost intervention.

The CCG recognises that early surgery is likely to be the most effective treatment option if there is evidence of nerve compression or significant functional impairment.

The CCG recognises that there is evidence of good outcomes and high levels of patient satisfaction following surgery.

Major complications of surgical release are rare. Complications such as, persistent symptoms, reduced grip strength, neurovascular injury and wound complications have been reported - usually in less than 1% of surgical patients. However, scar tenderness and pillar pain are reported more frequently and may persist for up to two years.

The CCG therefore considers that, in circumstances other than those described in section 1 of the policy, the potential risks associated with surgery outweigh the potential benefits.

The CCG considers that in mild to moderate cases, management of carpal tunnel syndrome by conservative methods (which may include splinting, activity modification and, if appropriate, a single local corticosteroid
injection), before considering surgery, represents the most cost-effective treatment strategy. This policy therefore relies on the principle of cost-effectiveness by requiring conservative management to be used before considering surgery.

6 Ethics

6.1 The CCG considers that the surgical release of the carpal tunnel meets the criterion for ethical healthcare delivery and therefore this policy does not rely on the Principle of Ethics.

7 Affordability

7.1 The CCG does not call into question the affordability of surgical carpal tunnel release and therefore this policy does not rely on the Principle of Affordability.

8 Exceptions

8.1 The CCG will consider exceptions to this policy in accordance with the Policy for Considering Applications for Exceptionality to Commissioning Policies.

8.2 In the event of inconsistency, this policy will take precedence over any non-mandatory NICE guidance in driving decisions of this CCG. A circumstance in which a patient satisfies NICE guidance but does not satisfy the criteria in this policy does not amount to exceptionality.

9 Force

9.1 This policy remains in force until it is superseded by a revised policy or by mandatory NICE guidance relating to this intervention, or to alternative treatments for the same condition.

9.2 In the event of NICE guidance referenced in this policy being superseded by new NICE guidance, then:

- If the new NICE guidance has mandatory status, then that NICE guidance will supersede this policy with effect from the date on which it becomes mandatory.
- If the new NICE guidance does not have mandatory status, then the CCG will aspire to review and update this policy accordingly. However, until the CCG adopts a revised policy, this policy will remain in force and any references in it to NICE guidance will remain valid as far as the decisions of this CCG are concerned.

10 References


7. Middleton SD & Anakwe RE, Carpal Tunnel Syndrome: Clinical Review. BMJ 2014;349:g6437 doi:10.1136/bmj.g6437 (Published 6 November 2014)


Date of adoption: 05 September 2019
Date for review: 05 September 2022